Drugs / BNT326
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07111520 | Sep 2025 → Jan 2029 expected | non-small cell lung carcinoma | BioNTech SE | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07070232 | Aug 2025 → Feb 2028 expected | neoplasm | BioNTech SE | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-08-19 | BioNTech SE | Lift of Partial Clinical Hold for BNT326/YL202 biontech.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT326 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07111520 ↗ |
| Route | Intravenous | “Intravenous (IV) infusion” NCT07070232 ↗ |